Published in Mol Pharmacol on January 01, 1976
Regulation of alpha genes of herpes simplex virus: the alpha 27 gene promoter-thymidine kinase chimera is positively regulated in converted L cells. J Virol (1982) 3.28
Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother (1986) 1.71
Unbiased metabolite profiling indicates that a diminished thymidine pool is the underlying mechanism of colon cancer chemoprevention by alpha-difluoromethylornithine. Cancer Discov (2013) 0.95
Compartmentation of guanine nucleotide precursors for DNA synthesis. Biochem J (1986) 0.95
Role of thymidylate synthetase activity in development of methotrexate cytotoxicity. Proc Natl Acad Sci U S A (1979) 0.93
Deoxynucleotide-interconverting enzymes and the quantification of deoxynucleoside triphosphates in mammalian cells. Biochem J (1982) 0.85
Synergistic interaction between 1-beta-D-arabinofuranosylcytosine, thymidine, and hydroxyurea against human B cells and leukemic blasts in vitro. Proc Natl Acad Sci U S A (1981) 0.79
Thymidylate synthetase-deficient mouse FM3A mammary carcinoma cell line as a tool for studying the thymidine salvage pathway and the incorporation of thymidine analogues into host cell DNA. Biochem J (1984) 0.77
Action of 2',2'-difluorodeoxycytidine on DNA synthesis. Cancer Res (1991) 3.57
Reversible polymers formed from self-complementary monomers using quadruple hydrogen bonding. Science (1997) 3.32
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine). Cancer Res (1990) 2.39
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res (1988) 2.03
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. Mol Pharmacol (1990) 1.88
Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst (1975) 1.72
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res (1993) 1.67
Using large clinical data sets to infer pathogenicity for rare copy number variants in autism cohorts. Mol Psychiatry (2012) 1.45
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res (1992) 1.40
A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem (1992) 1.38
Consequences of inhibition of guanine nucleotide synthesis by mycophenolic acid and virazole. Cancer Res (1977) 1.28
In vitro and in vivo antitumor activity of the phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer Res (1995) 1.20
Modeling the functional genomics of autism using human neurons. Mol Psychiatry (2011) 1.17
Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol Psychiatry (2010) 1.15
Low-pass genome-wide sequencing and variant inference using identity-by-descent in an isolated human population. Genetics (2011) 0.99
Micro procedure for determination of pyrophosphate and orthophosphate. Anal Biochem (1970) 0.98
Sulfonimidamide analogs of oncolytic sulfonylureas. J Med Chem (1997) 0.96
Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res (1992) 0.96
Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res (1996) 0.95
A novel class of monoglutamated antifolates exhibits tight-binding inhibition of human glycinamide ribonucleotide formyltransferase and potent activity against solid tumors. Cancer Res (1994) 0.95
Deoxyadenosine metabolism and toxicity in cultured L5178Y cells. Cancer Res (1977) 0.93
Characterization of the intracellular distribution and binding in human adenocarcinoma cells of N-(4-azidophenylsulfonyl)-N'-(4-chlorophenyl)urea (LY219703), a photoaffinity analogue of the antitumor diarylsulfonylurea sulofenur. Biochem Pharmacol (1995) 0.92
Evaluation of ribonucleoside and deoxyribonucleoside triphosphate pools in cultured leukemia cells during exposure to methotrexate or methotrexate plus thymidine. Cancer Res (1979) 0.91
Isolation of a DNA polymerase alpha-associated regulatory protein from calf thymus. Cancer Res (1979) 0.89
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs (1996) 0.89
Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Cancer Res (1979) 0.88
Adriamycin and daunorubicin: a comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res (1973) 0.88
Sulfonylureas: a new class of cancer chemotherapeutic agents. J Med Chem (1992) 0.87
Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol (1993) 0.87
The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul (1996) 0.87
Synthesis and antitumor activity of 5-deaza-5,6,7,8-tetrahydrofolic acid and its N10-substituted analogues. J Med Chem (1989) 0.87
Comparison of MultiMap and TSP/CONCORDE for constructing radiation hybrid maps. J Hered (2003) 0.87
Interaction of drugs inhibiting different steps in the synthesis of DNA. Cancer Res (1972) 0.87
Partial deficiency of hypoxanthine-guanine phosphoribosyltransferase with reduced affinity for PP-ribose-P in four related males with gout. Hum Genet (1984) 0.86
Characterization of folate receptor from normal and neoplastic murine tissue: influence of dietary folate on folate receptor expression. Clin Cancer Res (1996) 0.86
Phase I trial of sulofenur (LY186641) given orally on a daily x 21 schedule. Anticancer Drugs (1994) 0.85
Thymidine induced perturbations in ribonucleoside and deoxyribonucleoside triphosphate pools in human leukemic CCRF-CEM cells. Mol Pharmacol (1979) 0.85
Increased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analogues. Cancer Chemother Pharmacol (1994) 0.84
Toxicity of naturally occurring purine deoxyribonucleosides. Pharmacol Ther (1980) 0.83
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs (1992) 0.83
Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine. Cancer Res (1978) 0.82
Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts. Biochem Pharmacol (1996) 0.80
Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Relationship to dideazatetrahydrofolate sensitivity. Biochem Pharmacol (1994) 0.80
Mathematical simulation of the interaction of drugs that inhibit deoxyribonucleic acid biosynthesis. Mol Pharmacol (1973) 0.80
DNA sequence and physical mapping of the canine transglutaminase 1 gene. Cytogenet Cell Genet (2001) 0.79
Biological effects of inhibition of guanine nucleotide synthesis by mycophenolic acid in cultured neuroblastoma cells. Cancer Res (1977) 0.79
Role of membrane-associated folate binding protein in the cytotoxicity of antifolates in KB, IGROV1, and L1210A cells. Oncol Res (1995) 0.78
Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. Cancer Res (1972) 0.78
Purine and pyrimidine metabolism: pathways, pitfalls and perturbations. Ciba Found Symp (1977) 0.78
Evidence for mitochondrial localization of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea in human colon adenocarcinoma cells. Cancer Res (1990) 0.78
Pharmacokinetics of the 5'-triphosphates of arabinosylcytosine and 2',2'-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser (1987) 0.78
Biochemical and antitumor effects of the combination of thymidine and 1-beta-D-arabinofuranosylcytosine against leukemia L1210. Cancer Res (1981) 0.78
Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs (1990) 0.77
Effects of allopurinol on the therapeutic efficacy of methotrexate. Cancer Res (1975) 0.77
Effect of albumin on antitumor activity of diarylsulfonylureas. Anticancer Res (1994) 0.76
Diarylsulfonylureas and radiotherapy. I. In vitro studies with N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea (Sulofenur). Cancer Commun (1991) 0.76
Potentiation by guanine nucleosides of the growth-inhibitory effects of adenosine analogs on L1210 and sarcoma 180 cells in culture. Cancer Res (1976) 0.76
Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer. J Natl Cancer Inst (1992) 0.76
Physical and radiation hybrid mapping of canine chromosome 12, in a region corresponding to human chromosome 6p12-q12. Genomics (2001) 0.76
Inhibition of calf thymus DNA polymerase-alpha by deoxyribonucleoside triphosphates. Mol Pharmacol (1980) 0.76
Cloning, sequence analysis and radiation hybrid mapping of a mammalian KRT2p gene. Funct Integr Genomics (2001) 0.75
Clinical pharmacology of the 6-thiopurines. Cancer Treat Rev (1979) 0.75
Effects of uracil derivatives on phosphorylation of arabinosylcytosine. Mol Pharmacol (1968) 0.75
Efficacy of sulofenur and a second generation diarylsulfonylurea, N-[5-(2,3-dihydrobenzofuryl)sulfonyl]-N'-(3,4-dichlorophenyl)urea (LY295501), against colon adenocarcinoma xenografts. Anticancer Drugs (1995) 0.75
Whole-body autoradiographic disposition and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient or regular diets. J Pharm Sci (1994) 0.75
Studies of the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkenyl)phosphocholines. J Med Chem (1986) 0.75
Multiple basis of combination chemotherapy. Cancer (1977) 0.75
Combinations of drugs which interact as inhibitors of DNA biosynthesis. Adv Enzyme Regul (1972) 0.75
Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion. Antibiot Chemother (1971) (1978) 0.75
Multifactorial cellular determinants of the action of antimetabolites. Adv Enzyme Regul (1976) 0.75
Enhancement by caffeine of the growth inhibitory effects of antimetabolites in lymphoma L5178Y cells. Biochem Pharmacol (1977) 0.75
Reduced nicotinamide adenine dinucleotide phosphate-dependent binding of competitive inhibitors to dihydrofolate reductase. Mol Pharmacol (1970) 0.75
Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias. Cancer Chemother Pharmacol (1996) 0.75
Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs. J Pharm Sci (1993) 0.75
4-Vinyl analog of pyridoxal, a potent antagonist of vitamin B6. J Med Chem (1973) 0.75
Synthesis and biological activity of acyclic analogues of 5,10-dideaza-5,6,7,8-tetrahydrofolic acid. J Med Chem (1992) 0.75
Antitumor activity of cytidine dialdehyde and its effects on nucleotide and nucleic acid synthesis. Cancer Res (1980) 0.75
Antitumor activity of N6-phenyladenosine, and inhibitor of adenosine utilization, in combination with related purine analogs. Cancer Res (1973) 0.75
Evaluation of N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol (1989) 0.75
Medicinal chemistry of difluoropurines. Semin Oncol (1995) 0.75
Studies on the cellular pharmacology of N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)-urea. Biochem Pharmacol (1990) 0.75
Comparison of metabolism and toxicity to the structure of the anticancer agent sulofenur and related sulfonylureas. Chem Res Toxicol (1992) 0.75
Biochemical and kinetic approaches to inhibition of multiple pathways. Pharmacol Ther (1979) 0.75
Synthesis and antitumor activity of LY288601, the 5,6-dihydro analog of LY231514. Adv Exp Med Biol (1993) 0.75
N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, a novel agent equally cytotoxic to nonproliferating human colon adenocarcinoma cells. Cancer Res (1990) 0.75
Sparing action of uridine on the activity of arabinosylcytosine with normal and leukemic mice. Cancer Res (1968) 0.75